Fractyl Health, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
GUTS Nasdaq 3840 fractyl.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fractyl Health, Inc.

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 - Nov 5th, 2025 5:00 am
Fractyl Health Unveils Potent Preclinical Data for Dual GIP/GLP-1 Gene Therapy RJVA-002 for Obesity - Oct 17th, 2025 7:59 am
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity - Oct 7th, 2025 5:00 am
Fractyl Health (GUTS) Is Up 35.6% After Revita Shows Weight Loss Maintained Post-GLP-1 and $60M Raise - Sep 28th, 2025 4:53 am
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock - Sep 26th, 2025 5:05 am
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation - Sep 26th, 2025 5:00 am
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth - Sep 3rd, 2025 5:00 am
Fractyl Health First Half 2025 Earnings: US$1.06 loss per share (vs US$0.57 loss in 1H 2024) - Aug 14th, 2025 5:41 am
Fractyl Health Inc (GUTS) Q2 2025 Earnings Call Highlights: Financial Discipline and Promising ... - Aug 13th, 2025 1:12 am
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates - Aug 12th, 2025 2:05 pm
Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares - Aug 7th, 2025 2:05 pm
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference - Aug 6th, 2025 2:05 pm
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering - Aug 6th, 2025 6:30 am
Fractyl Health Announces Proposed Public Offering - Aug 5th, 2025 2:15 pm
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure - Aug 5th, 2025 2:02 pm
Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS) - Jul 29th, 2025 8:23 am
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy - Jun 23rd, 2025 5:40 am
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models - Jun 23rd, 2025 5:30 am
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing - Jun 18th, 2025 5:00 am
Biotech Alert: Searches spiking for these stocks today - Jun 13th, 2025 9:55 am